Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-degrading enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).

Hansa’s research and development program is advancing the next generation of the Company’s enzyme technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the US.